Search

Your search keyword '"Han, Ma Ai Thanda"' showing total 37 results
Start Over Author "Han, Ma Ai Thanda"
37 results on '"Han, Ma Ai Thanda"'

1. FRI-236-YI Racial disparities in incidence of cirrhosis and extrahepatic manifestations in metabolic dysfunction-associated steatotic liver disease

Author

Aboona, Majd, primary, Ghani, Leith, additional, Rangan, Pooja, additional, Chen, Vincent, additional, Ng, Cheng Han, additional, Huang, Daniel, additional, Muthiah, Mark, additional, Kim, Donghee, additional, Rubin, Moises Nevah, additional, Han, Ma Ai Thanda, additional, Fallon, Michael, additional, and Wijarnpreecha, Karn, additional

Published
2024
Full Text
View/download PDF

2. Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study.

Author

Aboona, Majd B., Faulkner, Claire, Rangan, Pooja, Ng, Cheng Han, Huang, Daniel Q., Muthiah, Mark, Nevah Rubin, Moises I., Han, Ma Ai Thanda, Fallon, Michael B., Kim, Donghee, Chen, Vincent L., and Wijarnpreecha, Karn

Subjects
ADULTS, AFRICANS, NATIVE Americans, BODY mass index, MORTALITY
Abstract

Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease and 10%–20% occurs in lean individuals. There is little data in the literature regarding outcomes in an ethnically‐diverse patient populations with MASLD. Thus, we aim to investigate the natural history and ethnic disparities of MASLD patients in a diverse population, and stratified by body mass index categories. Methods: We conducted a retrospective multicenter study on patients with MASLD at the Banner Health System from 2012 to 2022. Main outcomes included mortality and incidence of cirrhosis, cardiovascular disease, diabetes mellitus (DM), liver‐related events (LREs), and cancer. We used competing risk and Cox proportional hazard regression analysis for outcome modelling. Results: A total of 51 452 (cross‐sectional cohort) and 37 027 (longitudinal cohort) patients were identified with 9.6% lean. The cohort was 63.33% European ancestry, 27.96% Hispanic ancestry, 3.45% African ancestry, and 2.31% Native American/Alaskan ancestry. Median follow‐up was 45.8 months. After adjusting for confounders, compared to European individuals, Hispanic and Native American/Alaskan patients had higher prevalence of cirrhosis and DM, and individuals of Hispanic, African, and Native American/Alaskan ancestry had higher mortality and incidence of LREs and DM. Lean patients had higher mortality and incidence of LREs compared with non‐lean patients. Conclusion: Native American/Alaskan, Hispanic, and African patients had higher mortality and incidence of LREs and DM compared with European patients. Further studies to explore the underlying disparities and intervention to prevent LREs in lean patients, particularly several ethnic groups, may improve clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria

Author

Yang, Alexander H., Han, Ma Ai Thanda, Samala, Niharika, Rizvi, Bisharah S., Marchalik, Rachel, Etzion, Ohad, Wright, Elizabeth C., Cao, Liang, Hakim, Frances T., Jones, Elizabeth, Kapuria, Devika, Hickstein, Dennis D., Fowler, Daniel, Kanakry, Jennifer A., Kanakry, Christopher G., Kleiner, David E., Koh, Christopher, Pavletic, Steven Z., and Heller, Theo

Published
2022
Full Text
View/download PDF

10. De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation

Author

Han, Ma Ai Thanda, Olivo, Raquel, Choi, Catherine J, and Pyrsopoulos, Nikolaos

Subjects
Metabolic dysfunction-associated fatty liver disease, surgical procedures, operative, Graft steatosis, Survival, Hepatology, Metabolic dysfunction-associated steatohepatitis, Minireviews, De novo, Recurrent, Fibrosis
Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new acronym adopted from the consensus of international experts. Given the increasing prevalence of MAFLD in pre-transplant settings, de novo and recurrent graft steatosis/MAFLD are common in post-transplant settings. The impact of graft steatosis on long-term outcomes is unclear. The current knowledge of incidence rate, risk factors, diagnosis, long-term outcomes, and management of graft steatosis (both de novo and recurrent) is discussed in this review.

Published
2021

11. Modifications decrease hepatic steatosis in Taiwanese with metabolic‐associated fatty liver disease

Author

Liu, Tso‐Tsai, primary, Qiu, He, additional, Liu, Shi‐Yu, additional, Chien, Chieh, additional, Wang, Jen‐Hung, additional, Wong, Ming‐Wun, additional, Yi, Chih‐Hsun, additional, Lin, Lin, additional, Lei, Wei‐Yi, additional, Liang, Shu‐Wei, additional, Hung, Jui‐Sheng, additional, Huang, Jee‐Fu, additional, Chen, Chien‐Lin, additional, and Han, Ma Ai Thanda, additional

Published
2022
Full Text
View/download PDF

15. Fr426 LIVER ABNORMALITIES IN TURNER'S SYNDROME

Author

Rai, Anjali, primary, Etzion, Ohad, additional, Han, Ma Ai Thanda, additional, Patel, Ruchi, additional, Ko, Christopher, additional, Kleiner, David, additional, Mousa, Omar Y., additional, Loomba, Rohit, additional, Bakalov, Vladimir, additional, Takyar, Varun, additional, and Heller, Theo, additional

Published
2021
Full Text
View/download PDF

21. MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study

Author

Han, Ma Ai Thanda, primary, Vipani, Aarshi, additional, Noureddin, Nabil, additional, Ramirez, Kim, additional, Gornbein, Jeffrey, additional, Saouaf, Rola, additional, Baniesh, Nader, additional, Cummings‐John, Oladuni, additional, Okubote, Toluwalase, additional, Setiawan, Veronica Wendy, additional, Rotman, Yaron, additional, Loomba, Rohit, additional, Alkhouri, Naim, additional, and Noureddin, Mazen, additional

Published
2020
Full Text
View/download PDF

22. Microbial Translocation in the Context of Hepatitis B Infection and Hepatitis D Infection.

Author

Townsend, Elizabeth C, Zhang, Grace Y, Ali, Rabab, Surana, Pallavi, Firke, Marian, Moon, Mi Sun, Han, Ma Ai Thanda, Gewirtz, Meital, Haddad, James A, Kleiner, David E, Koh, Christopher, and Heller, Theo

Subjects
HEPATITIS D virus, HEPATITIS B, HEPATITIS B virus, CHRONIC hepatitis B, BACTERIAL DNA, PLANT translocation
Abstract

Background Increased microbial translocation (MT) into the systemic circulation is associated with liver disease progression. Microbial translocation has yet to be completely defined in chronic hepatitis B virus (HBV) and chronic hepatitis delta virus (HDV). Methods Our aim was to characterize MT and associated immune response in chronic HBV and HDV at various stages of disease. Serum from 53 HBV, 43 HDV, and 36 healthy control (HC) subjects was obtained. Subjects were categorized by aspartate aminotransferase-to-platelet ratio index into mild (<0.5), moderate, and severe (>1.0) disease. Cytokines, microbial products, and microbial deoxyribonucleic acid (DNA) levels were assessed in a single treatment-naive time point for each patient. Next-generation sequencing identified bacterial species present within patient sera. Results The HBV and HDV subjects display higher serum concentrations of Gram-negative (G−) bacterial lipopolysaccharide and fungal beta-glucan compared with HC (all P <.01). Gram-positive (G+) bacterial peptidoglycan is higher in HBV compared to HDV and HC (both P <.0001). Within both disease cohorts, peptidoglycan correlates with interleukin (IL)-1b, IL-8, IL-12p70, and IL-13 (all Spearman's rho >0.45; P <.05). Next-generation sequencing from 7 subjects with detectable serum bacterial DNA revealed changes in abundance of bacterial taxa and a higher proportion of Gram-positive genera in severe disease. Greater G+/G− taxa ratio is associated with higher cytokine levels and disease markers. Conclusions The HBV and HDV patients display increased translocation of bacterial and fungal products into serum. An increased proportion of Gram-positive genera is associated with disease progression. Correlations of peptidoglycan with antimicrobial cytokines suggest that particular microbial classes may contribute to systemic inflammation and possibly disease progression. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

23. SAT-298-MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study

Author

Han, Ma Ai Thanda, primary, Grotts, Jonathan, additional, Saouaf, Rola, additional, Noureddin, Nabil, additional, Ayoub, Walid, additional, Scott, Andrea, additional, Barbara, Mary, additional, Tjahja, Matthew, additional, Okubote, Toluwalase, additional, Kayali, Dr. Zeid, additional, Mena, Edward, additional, Alkhouri, Naim, additional, and Noureddin, Mazen, additional

Published
2019
Full Text
View/download PDF

24. THU-311-Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study

Author

Han, Ma Ai Thanda, primary, Saouaf, Rola, additional, Noureddin, Nabil, additional, Grotts, Jonathan, additional, Sundaram, Vinay, additional, Scott, Andrea, additional, Mansouri, Mahsa, additional, Barbara, Mary, additional, Tjahja, Matthew, additional, Thomas, Emmanuel, additional, Kayali, Zeid, additional, Mena, Edward, additional, Alkhouri, Naim, additional, and Noureddin, Mazen, additional

Published
2019
Full Text
View/download PDF

25. A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C

Author

Koh, Christopher, primary, Dubey, Preeti, additional, Han, Ma Ai Thanda, additional, Walter, Peter J., additional, Garraffo, H. Martin, additional, Surana, Pallavi, additional, Southall, Noel T., additional, Borochov, Nathaniel, additional, Uprichard, Susan L., additional, Cotler, Scott J., additional, Etzion, Ohad, additional, Heller, Theo, additional, Dahari, Harel, additional, and Liang, T. Jake, additional

Published
2019
Full Text
View/download PDF

27. Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease

Author

Ralph, Sinkus, Gharib, Ahmed, Han, Ma Ai Thanda, Meissner, Eric, Kleiner, David, Zhao, Xiongce, McLaughlin, Mary, Matthews, Lindsay, Rizvi, Bisharah, Abd-Elmoniem, Khaled, Sinkus, Ralph, Levy, Elliot, Koh, Christopher, Myers, Robert, Subramanian, G. Mani, Kottilil, Shyam, Heller, Theo, Kovacs, Joseph, Morse, Caryn, Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), and Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, Article Subject, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Portal venous pressure, lcsh:Medicine, HIV Infections, Hepatic Veins, Antibodies, Monoclonal, Humanized, Gastroenterology, General Biochemistry, Genetics and Molecular Biology, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Vascular Stiffness, Fibrosis, Internal medicine, Hypertension, Portal, Pressure, Medicine, Humans, ComputingMilieux_MISCELLANEOUS, Aged, General Immunology and Microbiology, business.industry, lcsh:R, General Medicine, Hepatitis C, Middle Aged, medicine.disease, 3. Good health, Magnetic resonance elastography, Antibodies, Anti-Idiotypic, Clinical trial, Disease Progression, Portal hypertension, Elasticity Imaging Techniques, 030211 gastroenterology & hepatology, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Female, Radiology, Amino Acid Oxidoreductases, business, Research Article
Abstract

Background.Portal hypertension, an elevation in the hepatic venous pressure gradient (HVPG), can be used to monitor disease progression and response to therapy in cirrhosis. Since obtaining HVPG measurements is invasive, reliable noninvasive methods of assessing portal hypertension are needed.Methods.Noninvasive markers of fibrosis, including magnetic resonance elastography (MRE) shear wave velocity, were correlated with histologic fibrosis and HVPG measurements in hepatitis C (HCV) and/or HIV-infected patients with advanced liver disease enrolled in a clinical trial of treatment with simtuzumab, an anti-LOXL2 antibody.Results.This exploratory analysis includes 23 subjects: 9 with HCV monoinfection, 9 with HIV and HCV, and 5 with HIV and nonalcoholic steatohepatitis. Median Ishak fibrosis score was 4 (range 1–6); 11 subjects (48%) had cirrhosis. Median HVPG was 6 mmHg (range 3–16). Liver stiffness measured by MRE correlated with HVPG (r=0.64,p=0.01), histologic fibrosis score (r=0.71,p=0.004), noninvasive fibrosis indices, including APRI (r=0.81,p<0.001), and soluble LOXL2 (r=0.82,p=0.001). On stepwise multivariate regression analysis, MRE was the only variable independently associated with HVPG (R2=0.377,p=0.02).Conclusions.MRE of the liver correlated independently with HVPG. MRE is a valid noninvasive measure of liver disease severity and may prove to be a useful tool for noninvasive portal hypertension assessment.Trial Registration Number. This trial is registered withNCT01707472.

Published
2017

28. Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection

Author

Canini, Laetitia, primary, Koh, Christopher, additional, Cotler, Scott J., additional, Uprichard, Susan L., additional, Winters, Mark A., additional, Han, Ma Ai Thanda, additional, Kleiner, David E., additional, Idilman, Ramazan, additional, Yurdaydin, Cihan, additional, Glenn, Jeffrey S., additional, Heller, Theo, additional, and Dahari, Harel, additional

Published
2017
Full Text
View/download PDF

30. Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease

Author

Gharib, Ahmed M., primary, Han, Ma Ai Thanda, additional, Meissner, Eric G., additional, Kleiner, David E., additional, Zhao, Xiongce, additional, McLaughlin, Mary, additional, Matthews, Lindsay, additional, Rizvi, Bisharah, additional, Abd-Elmoniem, Khaled Z., additional, Sinkus, Ralph, additional, Levy, Elliot, additional, Koh, Christopher, additional, Myers, Robert P., additional, Subramanian, G. Mani, additional, Kottilil, Shyam, additional, Heller, Theo, additional, Kovacs, Joseph A., additional, and Morse, Caryn G., additional

Published
2017
Full Text
View/download PDF

33. Sa1006 Noninvasive Measures of Severity in Chronic Liver Disease, Moving Beyond Fibrosis.

Author

Han, Ma Ai Thanda, primary, Gharib, Ahmed M., additional, Zhao, Xiongce, additional, Sinkus, Ralph, additional, Rizvi, Bisharah S., additional, Matthews, Lindsay, additional, McLaughlin, Mary, additional, Kanwar, Bittoo, additional, Paulson, Matthew, additional, Subramanian, G.M., additional, Meissner, Eric, additional, Kottilil, Shyam, additional, Kleiner, David E., additional, Koh, Christopher, additional, Heller, Theo, additional, and Morse, Caryn G., additional

Published
2015
Full Text
View/download PDF

37. Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally.

Author

Han MAT, Yu Q, Tafesh Z, and Pyrsopoulos N

Abstract

Globally, the rise in prevalence of obesity and metabolic syndrome as a whole has been linked to increased access to processed foods, such as refined sugars and saturated fats. Consequently, nonalcoholic fatty liver disease (NAFLD) is on the rise in both developed and developing nations. However, much is still unknown on the NAFLD phenotype with regards to the effect of ethnic diversity. Despite similarities in dietary habits, it appears that certain ethnicities are more protected against NAFLD than others. However, manifestations of the same genetic polymorphisms in different groups of people increase those individuals' predisposition to NAFLD. Diets from different regions have been associated with a lower prevalence of NAFLD and have even been linked to regression of hepatic steatosis. Socioeconomic variations amongst different regions of the world also contribute to NAFLD prevalence and associated complications. Thus, a thorough understanding of ethnic variability in NAFLD is essential to tailoring treatment recommendations to patients of different backgrounds., Competing Interests: The authors have no conflict of interests related to this publication., (© 2021 Authors.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results